Prospective Biomarkers of SARS-CoV-2 Vaccine Seroconversion in Patients with Haematological Malignancies

Sophie C. Hamann(The University of Queensland), Andrea Henden(The University of Queensland), Kirk Morris(Royal Brisbane and Women's Hospital), Corey Smith(QIMR Berghofer Medical Research Institute), Siok‐Keen Tey(The University of Queensland), Katie E. Lineburg(QIMR Berghofer Medical Research Institute), K. Guppy-Coles(Queensland Health), Justine Leach(Royal Brisbane and Women's Hospital), Jyothy Raju(QIMR Berghofer Medical Research Institute), Louise Ng(QIMR Berghofer Medical Research Institute), Annabel Waugh(QIMR Berghofer Medical Research Institute), Laetitia Le Texier(QIMR Berghofer Medical Research Institute), Christine Bristow(Royal Brisbane and Women's Hospital), Michelle M. Spanevello(Royal Brisbane and Women's Hospital), Stuart Olver(QIMR Berghofer Medical Research Institute), Pauline Crooks(QIMR Berghofer Medical Research Institute)
Vaccines
February 25, 2026
10.3390/vaccines14030201
Cited by 0

Related Papers

Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
|Cancer Discovery|2019|272
Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients.
|Journal of Clinical Pathology|1984|261
Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin lymphoma patients
|Blood|2006|250
A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses
|Proceedings of the National Academy of Sciences|2004|235
BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies
|Clinical Microbiology Reviews|2017|226